Drug intelligence / Profile preview

dopamine + metaraminol

Development stage
Unknown
Modality
Small Molecules
Administration
Intravenous
01

Overview

Dopamine + metaraminol is a combination of two sympathomimetic agents used to manage acute hypotension, particularly in critical care and perioperative settings. Dopamine acts as a catecholamine neurotransmitter and vasopressor, stimulating dopaminergic receptors at low doses, beta-1 adrenergic receptors at moderate doses (increasing cardiac output), and alpha-1 adrenergic receptors at higher doses (causing vasoconstriction). Metaraminol is primarily an alpha-1 adrenergic receptor agonist with some indirect action via norepinephrine release and minor beta-adrenergic effects; it increases peripheral vascular resistance and blood pressure. The combination may be used when rapid hemodynamic support is required, leveraging both direct vasoconstrictive effects (metaraminol) and inotropic/vasopressor actions (dopamine)[1][2][3][7][10].

Brand names
None known for the fixed combination
Other names
None known for the fixed combination
02

Targets

ADRA1A (α1A)NET (Norepinephrine Transporter)DRD1 (Dopamine D1 Receptor)ADRB1 (β1)

Beyond the preview

Go deeper on dopamine + metaraminol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dopamine + metaraminol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call